• linkedin
  • Increase Font
  • Sharebar

    Atopic dermatitis: Biologics to watch in 2018

     

    Targeting IL-31

    Two IL-31 targeting agents to watch are BMS-981164, an anti IL-31 monoclonal antibody that can be given subcutaneously or intravenously, and nemolizumab (also called CIM331), which blocks binding to the IL31 alphareceptor (IL-31RA) and is primarily being studied as an injectable treatment for pruritus.

    Overexpression of IL-31 leads to pruritus, alopecia, and skin lesions in mice, the authors wrote, and in humans, has been associated with late onset itch and is thought to promote AD and pruritus pathophysiology through the “scratch-itch cycle.”

    A phase 1 trial of BMS-981164 has been completed but not reported, authors said, and a randomized, placebo-controlled phase 2 trial of nemolizumab showed that tin patients with previously uncontrolled moderate-to-severe AD, the agent “rapidly and consistently” improved AD as well as pruritus and sleep disturbance.

    NEXT: Targeting IL-22 and IL-17

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow